Related Experiment Videos
[New aspects of blood component therapy]
C Dettmann1, M Weippert, J Roewer
1Gebietsblutspendezentrale des Bezirkskrankenhauses Wismar.
Anaesthesiologie Und Reanimation
|January 1, 1990
Summary
Cryo-poor plasma (CPP) can replace fresh frozen plasma (FFP) in most cases for producing factor VIII. This improves the availability of factor VIII for treating haemophilia A patients.
Area of Science:
- Hematology
- Blood component therapy
Context:
- Increasing demand for factor VIII in haemophilia A treatment.
- Fresh frozen plasma (FFP) is the primary source for factor VIII production.
- Clinical use of FFP has significantly increased.
Purpose:
- To evaluate cryo-poor plasma (CPP) as an alternative to FFP for factor VIII production.
- To address the growing FFP demand and improve factor VIII supply.
Summary:
- Cryo-poor plasma (CPP) is a blood component with low levels of factor VIII and fibrinogen, clinically insignificant.
- CPP can be substituted for FFP in 95% of applications.
- This substitution increases FFP availability for factor VIII manufacturing.
Impact:
- Enhanced supply of factor VIII for haemophilia A patients.
- Improved resource allocation within blood banking services.
- Potential for broader access to essential haemophilia treatments.